Loading...
XSTOATORX
Market cap18mUSD
Dec 23, Last price  
0.26SEK
1D
-1.13%
1Q
-80.19%
Jan 2017
-99.24%
IPO
-99.29%
Name

Alligator Bioscience AB

Chart & Performance

D1W1MN
XSTO:ATORX chart
P/E
—
P/S
3.44
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
27.32%
Rev. gr., 5y
16.60%
Revenues
58m
+62.78%
1,234,000289,797,00058,240,00056,875,00026,959,0004,358,0004,352,00012,943,00035,696,00058,107,000
Net income
-249m
L+28.54%
-76,782,000207,377,000-48,356,000-63,758,000-150,043,000-210,531,000-143,609,000-141,967,000-193,397,000-248,586,000
CFO
-189m
L+9.66%
-62,736,000204,894,000-37,610,000-99,629,000-104,115,000-178,963,000-141,352,000-127,033,000-172,607,000-189,285,000
Earnings
Feb 06, 2025

Profile

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. The company develops Mitazalimab, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of cancer. The company also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a research collaboration with MacroGenics, Inc. to develop a novel immunotherapy. The company also has a joint research agreement with BioArctic AB (publ) to employ proprietary antibody generation technologies for developing new product candidates; and a research collaboration and license agreement with the Orion Corporation to discover and develop new bispecific antibody cancer therapeutics. Alligator Bioscience AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
URL
https://alligatorbioscience.se/
IPO date
Nov 23, 2016
Employees
61
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
58,107
62.78%
35,696
175.79%
12,943
197.40%
Cost of revenue
483,377
282,651
173,964
Unusual Expense (Income)
NOPBT
(425,270)
(246,955)
(161,021)
NOPBT Margin
Operating Taxes
(6)
231
Tax Rate
NOPAT
(425,270)
(246,949)
(161,252)
Net income
(248,586)
28.54%
(193,397)
36.23%
(141,967)
-1.14%
Dividends
Dividend yield
Proceeds from repurchase of equity
195,455
426
342,665
BB yield
-63.25%
-0.12%
-90.12%
Debt
Debt current
8,581
8,499
6,225
Long-term debt
23,613
40,505
13,247
Deferred revenue
Other long-term liabilities
1,000
Net debt
(33,924)
(50,116)
(258,676)
Cash flow
Cash from operating activities
(189,285)
(172,607)
(127,033)
CAPEX
(2,459)
(440)
(45)
Cash from investing activities
(2,459)
(440)
(45)
Cash from financing activities
161,561
(7,827)
301,795
FCF
(406,337)
(258,466)
(153,432)
Balance
Cash
66,118
97,305
278,148
Long term investments
1,815
Excess cash
63,213
97,335
277,501
Stockholders' equity
(1,043,369)
(822,848)
(629,558)
Invested Capital
1,071,321
936,402
921,567
ROIC
ROCE
EV
Common stock shares outstanding
448,490
220,585
147,956
Price
0.69
-55.55%
1.55
-39.69%
2.57
-66.30%
Market cap
309,009
-9.62%
341,907
-10.08%
380,246
-57.66%
EV
275,085
291,792
121,570
EBITDA
(414,781)
(235,188)
(149,877)
EV/EBITDA
Interest
483
646
231
Interest/NOPBT